The Biomedical Catalyst (BMC) provides grant funding to bioscience companies for the translation of innovative scientific ideas into products and therapies for patients. It is run by Innovate UK and the Medical Research Council with additional funding from Scottish Enterprise. 

The BIA was instrumental in securing the launch of the BMC in 2011 and made its continuation a key campaign focus. The economic and scientific impacts of the scheme have been demonstrated in BIA analysis.

In June 2020, Innovate UK’s CEO Ian Campbell confirmed that the Biomedical Catalyst was to be relaunched, allowing innovative biotech companies to access a share of £30 million in grant funding. The relaunch was the direct result of consistent campaigning by the BIA and our members to ensure that this key source of early-stage funding for UK bioscience companies will continue to support the development of new life-changing medical treatments, diagnostics and devices, and underpin economic growth for the future. Read more about the BIA's decade long campaign for the BMC here

To check for open BMC competitions and other Innovate UK funding opportunities use the link below.

 

See how the Biomedical Catalyst has helped BIA members Arecor and MediSieve:

 

"The BIA has been the driving force in making a compelling case for the interests of UK life science SMEs in Whitehall and Westminster. Your campaign to re-fund the Biomedical Catalyst, with tangible case studies of private sector investment crowded-in by the Catalyst, made a vital difference in ensuring the programme's continuation. As we set out the next stage of the Life Science Industrial Strategy we need the BIA's voice of the small and new companies."

George Freeman MP, Minister for Life Science 2014-16 and Chair of the Prime Minister's Policy Board